KR101406248B1 - 신규 헤테로아릴 치환된 벤조티아졸 - Google Patents

신규 헤테로아릴 치환된 벤조티아졸 Download PDF

Info

Publication number
KR101406248B1
KR101406248B1 KR1020087020871A KR20087020871A KR101406248B1 KR 101406248 B1 KR101406248 B1 KR 101406248B1 KR 1020087020871 A KR1020087020871 A KR 1020087020871A KR 20087020871 A KR20087020871 A KR 20087020871A KR 101406248 B1 KR101406248 B1 KR 101406248B1
Authority
KR
South Korea
Prior art keywords
delete delete
benzothiazol
alkyl
compound
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020087020871A
Other languages
English (en)
Korean (ko)
Other versions
KR20080090542A (ko
Inventor
일파 그라펜포르스
카트린 요나손
요나스 말름스트룀
구나 노르드팔
다비드 피링
칸 슬리포
다니엘 손
페터 스트룀
다비드 벤스보
Original Assignee
나비디아 바이오파마슈티컬즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38309497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101406248(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 나비디아 바이오파마슈티컬즈, 인크. filed Critical 나비디아 바이오파마슈티컬즈, 인크.
Publication of KR20080090542A publication Critical patent/KR20080090542A/ko
Application granted granted Critical
Publication of KR101406248B1 publication Critical patent/KR101406248B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020087020871A 2006-01-27 2007-01-25 신규 헤테로아릴 치환된 벤조티아졸 Expired - Fee Related KR101406248B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76265406P 2006-01-27 2006-01-27
US60/762,654 2006-01-27
PCT/SE2007/000068 WO2007086800A1 (en) 2006-01-27 2007-01-25 Novel heteroaryl substituted benzothiazoles

Publications (2)

Publication Number Publication Date
KR20080090542A KR20080090542A (ko) 2008-10-08
KR101406248B1 true KR101406248B1 (ko) 2014-06-19

Family

ID=38309497

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087020871A Expired - Fee Related KR101406248B1 (ko) 2006-01-27 2007-01-25 신규 헤테로아릴 치환된 벤조티아졸

Country Status (20)

Country Link
US (2) US8163928B2 (cg-RX-API-DMAC7.html)
EP (1) EP1981883A4 (cg-RX-API-DMAC7.html)
JP (1) JP5289061B2 (cg-RX-API-DMAC7.html)
KR (1) KR101406248B1 (cg-RX-API-DMAC7.html)
CN (1) CN101410393B (cg-RX-API-DMAC7.html)
AR (1) AR059178A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007207904C1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0707283A2 (cg-RX-API-DMAC7.html)
CA (1) CA2640213A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP088645A (cg-RX-API-DMAC7.html)
IL (1) IL192876A0 (cg-RX-API-DMAC7.html)
NO (1) NO20083394L (cg-RX-API-DMAC7.html)
NZ (1) NZ569667A (cg-RX-API-DMAC7.html)
RU (1) RU2448106C2 (cg-RX-API-DMAC7.html)
SA (1) SA07280009B1 (cg-RX-API-DMAC7.html)
TW (2) TW201018678A (cg-RX-API-DMAC7.html)
UA (1) UA95267C2 (cg-RX-API-DMAC7.html)
UY (1) UY30112A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007086800A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200806075B (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201018678A (en) 2006-01-27 2010-05-16 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
TW200813035A (en) 2006-06-19 2008-03-16 Astrazeneca Ab Novel heteroaryl substituted benzoxazoles
TW200901998A (en) 2007-03-06 2009-01-16 Astrazeneca Ab Novel 2-heteroaryl substituted benzothiophenes and benzofuranes
US8557222B2 (en) 2008-04-04 2013-10-15 Avid Radiopharmaceuticals, Inc. Radiopharmaceutical imaging of neurodegenerative diseases
US8530483B2 (en) 2008-05-30 2013-09-10 Merck Sharp & Dohme Corp. Substituted azabenzoxazoles
US8193363B2 (en) * 2008-08-29 2012-06-05 Astrazeneca Ab Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits
US20110212031A1 (en) * 2008-10-31 2011-09-01 Cyrille Sur Novel substituted azabenzoxazoles
US20120263646A1 (en) * 2009-10-15 2012-10-18 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
JP6069661B2 (ja) * 2010-06-24 2017-02-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 種々のアミロイドβペプチドアロフォームレベルの調節における組成物及びその使用
WO2012145169A2 (en) 2011-04-21 2012-10-26 The Regents Of The University Of California Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles
US20140348748A1 (en) * 2011-09-16 2014-11-27 Lisheng Cai Beta-amyloid imaging agents, methods of manufacture, and methods of use thereof
CN102558091B (zh) * 2011-12-22 2014-10-08 合肥工业大学 一种苯并噻唑类衍生物及其用途
CN102659772B (zh) * 2012-05-03 2015-02-11 北京师范大学 一种与Aβ斑块有亲和力的2-芳基苯并杂环化合物及其制备方法和应用
JP5422782B1 (ja) 2012-12-21 2014-02-19 独立行政法人放射線医学総合研究所 脳内に蓄積したタウタンパク質をイメージングするための新規化合物
EP2968296B1 (en) 2013-03-12 2020-09-02 The Regents of the University of California Gamma-secretase modulators
TWI652014B (zh) 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
WO2015051188A1 (en) 2013-10-02 2015-04-09 Washington University Heterocyclic molecules for biomedical imaging and therapeutic applications
WO2016004513A1 (en) * 2014-07-11 2016-01-14 Simon Fraser University Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods
WO2016010092A1 (ja) 2014-07-16 2016-01-21 国立研究開発法人科学技術振興機構 ベンゾチアゾール化合物及びこれを含有する医薬
MX381224B (es) 2014-10-31 2025-03-12 Massachusetts Gen Hospital Potentes moduladores de gamma-secretasa.
CN107207490A (zh) * 2014-12-02 2017-09-26 拜耳作物科学股份公司 作为害虫防治剂的双环化合物
WO2016087343A1 (de) 2014-12-02 2016-06-09 Bayer Pharma Aktiengesellschaft Heteroaryl-substituierte imidazo[1,2-a]pyridine und ihre verwendung
KR102536024B1 (ko) * 2015-03-12 2023-05-24 에프엠씨 코포레이션 헤테로환-치환 이환 아졸 살충제
CA2995847C (en) * 2015-08-28 2024-05-28 Chdi Foundation, Inc. Probes for imaging huntingtin protein
GB201617339D0 (en) * 2016-10-12 2016-11-23 Lytix Biopharma As Therapeutic compounds
CA3071525A1 (en) 2017-08-02 2019-02-07 Spinogenix, Inc. Benzothiazole and related compounds
GB201806004D0 (en) 2018-04-11 2018-05-23 Karin & Sten Mortstedt Cbd Solutions Ab Selective ligands for TAU aggregates
CN112384517B (zh) 2018-05-09 2023-07-14 新旭生技股份有限公司 杂芳基化合物及其用途
CN112105393A (zh) * 2018-05-16 2020-12-18 爱默蕾大学 苯乙烯基苯并噻唑衍生物及在成像中的用途
ES3032326T3 (en) * 2019-01-31 2025-07-17 Spinogenix Inc Solid forms of a promoter of spinogenesis
GB201914989D0 (en) * 2019-10-16 2019-11-27 Karin & Sten Mortstedt Cbd Solutions Ab Selective ligands for TAU Aggregates
CA3161455A1 (en) 2019-11-13 2021-05-20 Aprinoia Therapeutics Limited Compounds for degrading tau protein aggregates and uses thereof
KR102682408B1 (ko) * 2021-05-12 2024-07-05 에이치케이이노엔 주식회사 신규한 벤조티아졸 유도체, 이의 제조방법 및 이의 간질환 예방 또는 치료 용도
CN114478431B (zh) * 2022-03-09 2024-07-02 台州学院 一种双取代苯并噻吩类钾离子通道激动剂的制备方法
CN114380731B (zh) * 2022-03-09 2024-07-02 台州学院 一种kcnq钾离子通道激动剂、药物组合物及其应用
JP2025540931A (ja) 2022-11-03 2025-12-17 セントニックス インコーポレイテッド タウ凝集体に対する選択的リガンド
UY41082A (es) 2024-03-28 2025-08-29 Pi Industries Ltd Compuestos bicíclicos condensados y su uso como agentes de control de plagas

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002051821A1 (en) 2000-12-22 2002-07-04 Astrazeneca Ab Therapeutic compounds

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU523040B2 (en) * 1978-05-15 1982-07-08 Kanebo Limited Calcium -antagonistic composition
GB8305245D0 (en) 1983-02-25 1983-03-30 Fujisawa Pharmaceutical Co Imidazo-heterocyclic compounds
US4556411A (en) * 1984-12-07 1985-12-03 Fmc Corporation Benzothiazole derivatives for plant growth and development modification
JPS6394248A (ja) 1986-10-08 1988-04-25 Canon Inc 電子写真感光体
CA2034309C (en) * 1990-01-22 1997-04-01 Takashi Iwaki Mesomorphic compound, liquid crystal composition containing same, liquid crystal device using same and display apparatus
JPH09507071A (ja) 1993-12-21 1997-07-15 イーライ・リリー・アンド・カンパニー アミロイド原性ペプチドに関連した状態を治療又は予防する方法
US5518713A (en) * 1995-02-13 1996-05-21 3V Inc. Benzoxazole derivatives, the use thereof as sunscreens and cosmetic compositions containing them
JPH11116476A (ja) 1997-10-16 1999-04-27 Sankyo Co Ltd 縮合複素環化合物
RU2324686C2 (ru) 2000-08-24 2008-05-20 Юнивесити Оф Питсбэг ПРОИЗВОДНЫЕ ТИОФЛАВИНА, СВЯЗЫВАЮЩИЕ АМИЛОИД, СПОСОБ ОБНАРУЖЕНИЯ in vivo ОТЛОЖЕНИЙ АМИЛОИДА И СПОСОБ РАСПОЗНАВАНИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА
US6596731B2 (en) 2001-03-27 2003-07-22 Hoffmann-La Roche Inc. Substituted imidazo[1,2-A] pyridine derivatives
CA2444214A1 (en) 2001-04-23 2002-10-31 The Trustees Of The University Of Pennsylvania Amyloid plaque aggregation inhibitors and diagnostic imaging agents
WO2003045929A1 (en) * 2001-11-26 2003-06-05 Takeda Chemical Industries, Ltd. Bicyclic derivative, process for producing the same, and use
GB0130305D0 (en) 2001-12-19 2002-02-06 Amersham Plc Compounds for imaging alzheimers disease
WO2003106439A1 (ja) 2002-06-12 2003-12-24 株式会社ビーエフ研究所 アミロイド蓄積性疾患の画像診断プローブ化合物、老人斑/びまん性老人斑染色用化合物、ならびにアミロイド蓄積性疾患の治療薬
TW200401194A (en) 2002-07-11 2004-01-16 Advanced Micro Devices Inc Method and apparatus for determining a processor state without interrupting processor operation
CA2494139A1 (en) 2002-08-02 2004-02-12 Genesoft Pharmaceuticals, Inc. Biaryl compounds having anti-infective activity
JP2004250411A (ja) 2003-02-21 2004-09-09 Bf Kenkyusho:Kk アミロイドβ蓄積性疾患の診断プローブおよび治療用化合物
CA2438032C (en) * 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
CA2521056A1 (en) 2003-03-31 2004-10-14 Daiichi Pharmaceutical Co., Ltd. Hydrazone derivative
US7329682B2 (en) * 2003-04-03 2008-02-12 Ewha University-Industry Collaboration Foundation Method for inhibiting 5-lipoxygenase using a benzoxazole derivative
WO2004101558A1 (en) * 2003-05-13 2004-11-25 F. Hoffmann-La Roche Ag 2-imidazo-benzothiazoles as adenosine receptor ligands
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
JP2008545663A (ja) 2005-05-27 2008-12-18 クイーンズ ユニバーシティ アット キングストン タンパク質フォールディング障害の治療
WO2007033080A2 (en) 2005-09-12 2007-03-22 Emory University Alzheimer's disease imaging agents
EP1937260A2 (en) 2005-09-16 2008-07-02 University of Pittsburgh In-vivo and in-vitro method for detecting amyloid deposits having at least one amyloidogenic protein
US8138360B2 (en) 2005-10-11 2012-03-20 University of Pittsburgh—of the Commonwealth System of Higher Education Isotopically-labeled benzofuran compounds as imaging agents for amyloidogenic proteins
EP1954287B2 (en) * 2005-10-31 2016-02-24 Merck Sharp & Dohme Corp. Cetp inhibitors
US8022075B2 (en) 2005-11-30 2011-09-20 Fujifilm Ri Pharma Co., Ltd. Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition
TW201018678A (en) 2006-01-27 2010-05-16 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
EP2023919A4 (en) * 2006-05-08 2010-12-22 Molecular Neuroimaging Llc COMPOUNDS AND AMYLOID PROBES FOR THERAPY AND IMAGING USES
TW200813035A (en) * 2006-06-19 2008-03-16 Astrazeneca Ab Novel heteroaryl substituted benzoxazoles
AU2008208091A1 (en) 2007-01-22 2008-07-31 Astrazeneca Ab Novel heteroaryl substituted imidazo [1,2 -a] pyridine derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002051821A1 (en) 2000-12-22 2002-07-04 Astrazeneca Ab Therapeutic compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Medicinal Chemistry, Vol. 46, No. 13, pp. 2740-2754, 2003. *

Also Published As

Publication number Publication date
US20120207679A1 (en) 2012-08-16
EP1981883A4 (en) 2010-10-06
JP5289061B2 (ja) 2013-09-11
AU2007207904A1 (en) 2007-08-02
US8163928B2 (en) 2012-04-24
CN101410393B (zh) 2012-01-25
TW200736252A (en) 2007-10-01
US8957215B2 (en) 2015-02-17
SA07280009B1 (ar) 2011-07-20
JP2009528271A (ja) 2009-08-06
BRPI0707283A2 (pt) 2011-04-26
WO2007086800A1 (en) 2007-08-02
AR059178A1 (es) 2008-03-12
ECSP088645A (es) 2008-08-29
CA2640213A1 (en) 2007-08-02
RU2448106C2 (ru) 2012-04-20
KR20080090542A (ko) 2008-10-08
RU2008130965A (ru) 2010-03-10
NZ569667A (en) 2011-09-30
IL192876A0 (en) 2009-02-11
AU2007207904C1 (en) 2011-10-13
UA95267C2 (en) 2011-07-25
ZA200806075B (en) 2012-12-27
UY30112A1 (es) 2007-08-31
CN101410393A (zh) 2009-04-15
AU2007207904B2 (en) 2011-03-10
NO20083394L (no) 2008-10-02
US20090028787A1 (en) 2009-01-29
EP1981883A1 (en) 2008-10-22
TW201018678A (en) 2010-05-16

Similar Documents

Publication Publication Date Title
JP5289061B2 (ja) 新規なへテロアリール置換ベンゾチアゾール
US7670591B2 (en) Heteroaryl substituted benzoxazoles
US7772256B2 (en) 2-heteroaryl substituted benzothiophenes and benzofuranes 709
KR20090101469A (ko) 신규 헤테로아릴 치환된 이미다조〔1,2­a〕피리딘 유도체
US20100098631A1 (en) Novel-2-Heteroaryl Substituted Indoles 695
RU2472789C2 (ru) Новые 2-гетероарил-замещенные бензотиофены и бензофураны 709
MX2008009396A (en) Novel heteroaryl substituted benzothiazoles

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20170604

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20170604

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000